Gem Aromatics Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs 104.0 Cr (+16.2% YoY) with PAT loss Rs 7.0 Cr; EBITDA margin 7.6%. Standalone PAT Rs 8.9 Cr. Dahej capex (~Rs 265 Cr) capitalised; new specialty molecules ramping.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Q2FY27 consolidated revenue Rs 104.0 Cr (+16.2% YoY) with PAT loss Rs 7.0 Cr; EBITDA margin 7.6%. Standalone PAT Rs 8.9 Cr. Dahej capex (~Rs 265 Cr) capitalised; new specialty molecules ramping.
Gem Aromatics reports Q1FY27 standalone revenue growth of 9% YoY. Strategy focuses on scaling the new Dahej facility and expanding into higher-value specialty molecules like cooling agents and phenol derivatives.
Gem Aromatics reports Q4 FY26 sequential recovery with consolidated revenue of ₹110cr (up 40% QoQ). Strategy focuses on diversifying from mint into high-margin clove derivatives and cooling agents via the new Dahej facility.
Gem Aromatics reports sequential recovery in Q4FY26 with revenue of ₹110 Cr (Consolidated). Focus is on ramp-up at the greenfield Dahej facility and higher-value specialty molecules.